Updates on Advanced Breast Cancer: Local Management and Other New Perspectives 2023

---

LIVEBreast CancerBreast Surgical OncologyBreast Medical OncologyInternal Medicine

Friday, May 12, 2023, 7:30 AM - Saturday, May 13, 2023, 1:00 PM, Marriott Medical Center Hotel Houston, Houston, TX


AMA PRA Category 1 Credits™ (10.00 hours), Non-Physician Attendance (10.00 hours)

This educational activity aims to enhance the knowledge of oncologists in the management of advanced breast cancer and how to implement the emerging therapies and cutting edge techniques into day-to-day practice. This activity will present the latest research updates and treatment trends/guideline for triple-negative breast cancer, inflammatory breast cancer, locally advanced breast cancer and metastatic breast cancer. Experts from both inside and outside of MD Anderson will address the importance of applying a multidisciplinary team approach to develop methods for identification of specific genomic and proteomic signatures of breast cancer. Clinical scenarios will be discussed to provide examples of a high level of patient-focused, multidisciplinary care a breast cancer patient should receive. Experts will also present on current clinical trials that offer novel therapies to treat advanced, rare and aggressive breast cancers. The goal is for healthcare professionals to develop the tools to diagnose, identify therapeutic approaches specifically for treatment of breast cancer, enhance approaches to assist in detecting the disease evaluate the effectiveness of treatment for advanced breast cancer patients, and appropriately refer patients to clinical trials if needed after the understanding of available therapy.

1. Recognize inflammatory and triple-negative breast cancer, and provide appropriate delivery of therapy that involves multidisciplinary care.
2. Develop skills in patient advocacy and support.
3. Implement the latest management techniques for locally advanced and recurrent breast cancer cases in their practice.
4. Integrate the latest biological discoveries and genomic findings into their clinical practice to improve patient outcomes.

This one and a half day conference on Updates on Advanced Breast Cancer: Local Management and other New Perspectives will begin on Friday, May 12, 2023, with Opening Remarks at 8:00 AM and will adjourn for the day at 1:00 PM.  The conference will reconvene on Saturday, May 14, 2022 at 7:50 AM and adjourn at 1:00 PM.

Advanced registration is encouraged as space is limited. If you are considering attending in-person and plan to register on-site, please use the link below to create a profile in PEP prior to arrival at the conference. https://mdanderson.cloud-cme.com/default.aspx

The deadline for advanced registration is Wednesday, April 26, 2023.

CONFERENCE REGISTRATION FEES

IN-PERSON ATTENDANCE Physicians - MDs, PhDs (MDACC, Non-TMC Members, Non-HAL)
Postmarked before April 26, 2023	$70.00
Postmarked after April 26, 2023	$80.00
IN-PERSON ATTENDANCE Physicians - MDs, PhDs (HAL, TMC Members, Non-MDACC)
Postmarked before April 26, 2023	$50.00
Postmarked after April 26, 2023	$60.00
IN-PERSON ATTENDANCE Healthcare Professionals, Trainees
Postmarked before April 26, 2023	$35.00
Postmarked after April 26, 2023	$45.00
IN-PERSON ATTENDANCE Patients, Caregiver, Advocates, and Volunteers
Postmarked before April 26, 2023	$0.00
Postmarked after April 26, 2023	$0.00
VIRTUAL ATTENDANCE Physicians - MDs, PhDs
Postmarked before April 26, 2023	$150.00
Postmarked after April 26, 2023	$150.00
VIRTUAL ATTENDANCE Healthcare Professionals, Trainees
Postmarked before April 26, 2023	$100.00
Postmarked after April 26, 2023	$100.00
VIRTUAL ATTENDANCE Patients, Caregiver, Advocates, and Volunteers
Postmarked before April 26, 2023	$50.00
Postmarked after April 26, 2023	$50.00
NOTE: Virtual Attendees Must Pre-Register by May 5

Virtual Attendance - live internet streaming (details and login information will be provided via emailed the week of the conference)
For more information, please call Continuing Professional Education (CPE), Learner Relations at 713-792-2223.

We accept the following forms of payment:

•  Credit Cards (MasterCard, VISA, and American Express)
• Check made payable to: The University of Texas MD Anderson Cancer Center (payable through U.S. banks only)

Mail to:    Continuing Professional Education – Unit 1781
The University of Texas MD Anderson Cancer Center
 P.O. Box 301407
 Houston, Texas 77230-1407

Telephone registrations are not accepted.

When registering online a receipt (confirmation) will be automatically emailed to the e-mail address you list on the registration form.

Refund/Cancellation Policy

The registration fee, minus a $15.00 administration-handling fee, is refundable if a written request is received on or before Wednesday, April 26, 2023.  No refunds will be granted after these dates. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check.

The Department of Continuing Professional Education (CPE), reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary.  Each registrant will be notified by mail, e-mail, or at the phone or fax numbers given on the registration form.  In case of activity cancellation, the liability of CPE, is limited to the registration fee.  CPE, will refund the full registration fee. 

CPE reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available. 

For additional information, contact CPE, at 713-792-2223 or toll free at 866-849-5866 or via e-mail: continuingeducation@mdanderson.org.

Special Assistance

Contact CPE, at 713-792-2223 or toll free at 866-849-5866 if you have any ADA accommodation needs.

Accreditation
In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation
The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 10.00 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

View the accessibility policy for The University of Texas M.D Anderson Cancer Center.

 

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Mitigation of Relevant Financial Relationships

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

 

The University of Texas MD Anderson Cancer Center and the conference organizing committee wishes to express appreciation to the following companies for their commitment by providing an educational grant in support of this continuing education activity.

AstraZeneca Pharmaceuticals

Novartis Pharmaceuticals Corporation

Varian Medical Systems, Inc.

 

 


This Acknowledgement recognizes confirmed supporters and exhibitors as of May 8, 2023.

 

---

 

The University of Texas MD Anderson Cancer Center and the conference organizing committee wishes to express appreciation to the following companies for exhibiting and/or sponsoring this continuing educational activity.

 

AstraZeneca Pharmaceuticals

 Daiichi Sankyo, Inc.

Eli Lilly and Company

Exact Sciences

Gilead Sciences

IBC Network Foundation

Merck

Novartis Pharmaceuticals Corporation

Pfizer Inc.

Seagen

Stemline Therapeutics

 


This Acknowledgement recognizes confirmed supporters and exhibitors as of May 10, 2023.

 

---

W9 Form Exhibit at this Event